Psychemedics Corporation Announces Record Revenues and Earnings

ACTON, Mass., Oct. 26, 2016  -- Psychemedics Corporation (PMD) today announced third quarter financial results for the period ended September 30, 2016.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of November 7, 2016 to be paid on November 17, 2016.  This will be the Company's 81st consecutive quarterly dividend.
 
The Company's revenue for the quarter ended September 30, 2016 increased 67% to $11.8 million, from $7.1 million for the quarter ended September 30, 2015.  Net income for the quarter ended September 30, 2016 increased 240% to $2.7 million or $0.49 per diluted share, from $796 thousand or $0.15 per diluted share for the comparable period last year. The Company's revenue for the nine months ended September 30, 2016 increased 35% to $28.2 million, from $20.8 million for the nine months ended September 30, 2015. Net income for the nine months ended September 30, 2016 increased 226% to $4.3 million or $0.79 per diluted share, from $1.3 million or $0.25 per diluted share for the comparable period last year.
Published: 27 October 2016
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Psychemedics Corporation ( PMD )

UPDATE – HTG Molecular Diagnostics and Merck KGaA, Darmstadt, Germany, Enter Into a Master Companion Diagnostics Agreement

TUCSON, Ariz., Oct. 11, 2016 - HTG Molecular Diagnostics, Inc. (HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Merck KGaA, Darmstadt, Germany, have entered a broad companion diagnostics master agreement. The initial development program agreement utilizes the HTG EdgeSeq DLBCL Cell of Origin Assay in the Merck KGaA, Darmstadt, Germany, M7583, selective and irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), program.
 
“We are honored to be chosen as the diagnostic development partner for Merck KGaA’s BTK program and our team is now focused on the near-term milestones.  Additionally, having a master companion diagnostic agreement paves the way for additional development collaborations,” stated TJ Johnson, HTG’s President and CEO.  “We have worked very hard to establish the organizational capabilities to support the development, regulatory filing and commercialization of companion diagnostics demonstrated by the recent CE/IVD marking of HTG’s DLBCL cell of origin assay,” added Mr. Johnson.
Published: 12 October 2016
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: HTG Molecular Diagnostics ( HTGM )

Genomic Health Reports Highest Test Growth in Two Years in Announcement of Third Quarter 2015 Financial Results

17% Increase in Tests Delivered; 6% Increase in Revenue
Continued Strong Growth in U.S. Breast Cancer Business with 11% Increase in Test Volume and 9% Increase in Revenue
Medicare Now Covering Oncotype DX Prostate Cancer Test
Conference Call Today at 4:30 p.m. ET

REDWOOD CITY, Calif., Nov. 3, 2015 -- Genomic Health, Inc. (GHDX) today reported financial results and business progress for the quarter ended September 30, 2015.

Revenue was $73.6 million in the third quarter of 2015 compared with $69.1 million for the third quarter of 2014, an increase of 6 percent. On a constant currency basis, revenue increased 8 percent compared with the same period in the prior year.

Published: 04 November 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Genomic Health Inc ( GHDX )